Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease.

Khoo J, Hsiang JC, Taneja R, Koo SH, Soon GH, Kam CJ, Law NM, Ang TL

Liver international : official journal of the International Association for the Study of the Liver24 Feb 2019Cited by 110 (Europe PMC)

PMID30721572DOI10.1111/liv.14065PepBankPUB-30721572

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In obese adults with NAFLD, liraglutide reduced body weight at 26 weeks, similar to the reduction with diet and exercise.
In plain wordsIn obese adults with fatty liver, liraglutide lowered body weight about as much as diet and exercise did over 26 weeks.
Peptide
Liraglutide
Outcome
DecreaseBody weight change at 26 weeks
Study
n = 30
Comparator
Diet and exercise (lifestyle modification)
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg daily · 26 weeksAs given in this study (human).
Measurements
Weight change
−3 kg
liraglutide group, 26 weeks
Weight change
−3.5 kg
diet and exercise group, 26 weeks
Source sentences
Summary
Diet and exercise and LI groups had significant (P < 0.01) and similar reductions in weight (-3.5 ± 3.3 vs -3.0 ± 2.2 kg), LFF (-8.1 ± 13.2 vs -7.0 ± 7.1%), serum alanine aminotransferase (-39 ± 35 vs -26 ± 33 U/L) and caspase-cleaved cytokeratin-18 (cCK-18) (-206 ± 252 vs -130 ± 158 U/L) at 26 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
or liraglutide 3 mg daily (LI group, n = 15) for 26 weeks
Summary · context
We compared the effects of weight loss induced with the glucagon-like peptide-1 agonist liraglutide, with that of lifestyle modification, followed by weight maintenance after discontinuing intervention, in obese adults with non-alcoholic fatty liver disease (NAFLD).
Report a problemFND-3072157201
02HumanRandomized controlled trialEfficacy outcome
In obese adults with NAFLD, liraglutide reduced liver fat fraction at 26 weeks, similar to the reduction with diet and exercise.
In plain wordsIn obese adults with fatty liver, liraglutide cut liver fat about as much as diet and exercise did over 26 weeks.
Peptide
Liraglutide
Outcome
DecreaseLiver fat fraction change at 26 weeks
Study
n = 30
Comparator
Diet and exercise (lifestyle modification)
Outcome group
Liver fat and liver function · Liver
Studied dose
3 mg daily · 26 weeksAs given in this study (human).
Measurements
Liver fat fraction change
−7%
liraglutide group, 26 weeks
Liver fat fraction change
−8.1%
diet and exercise group, 26 weeks
Source sentences
Summary
Diet and exercise and LI groups had significant (P < 0.01) and similar reductions in weight (-3.5 ± 3.3 vs -3.0 ± 2.2 kg), LFF (-8.1 ± 13.2 vs -7.0 ± 7.1%), serum alanine aminotransferase (-39 ± 35 vs -26 ± 33 U/L) and caspase-cleaved cytokeratin-18 (cCK-18) (-206 ± 252 vs -130 ± 158 U/L) at 26 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
or liraglutide 3 mg daily (LI group, n = 15) for 26 weeks
Summary · context
We compared the effects of weight loss induced with the glucagon-like peptide-1 agonist liraglutide, with that of lifestyle modification, followed by weight maintenance after discontinuing intervention, in obese adults with non-alcoholic fatty liver disease (NAFLD).
Report a problemFND-3072157202
03HumanRandomized controlled trialEfficacy outcome
In obese adults with NAFLD, liraglutide reduced serum alanine aminotransferase at 26 weeks, similar to the reduction with diet and exercise.
In plain wordsIn obese adults with fatty liver, liraglutide lowered a liver enzyme (ALT) about as much as diet and exercise did.
Peptide
Liraglutide
Outcome
DecreaseSerum ALT change at 26 weeks
Study
n = 30
Comparator
Diet and exercise (lifestyle modification)
Outcome group
Liver fat and liver function · Liver
Studied dose
3 mg daily · 26 weeksAs given in this study (human).
Measurements
ALT change
−26 U/L
liraglutide group, 26 weeks
ALT change
−39 U/L
diet and exercise group, 26 weeks
Source sentences
Summary
Diet and exercise and LI groups had significant (P < 0.01) and similar reductions in weight (-3.5 ± 3.3 vs -3.0 ± 2.2 kg), LFF (-8.1 ± 13.2 vs -7.0 ± 7.1%), serum alanine aminotransferase (-39 ± 35 vs -26 ± 33 U/L) and caspase-cleaved cytokeratin-18 (cCK-18) (-206 ± 252 vs -130 ± 158 U/L) at 26 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
or liraglutide 3 mg daily (LI group, n = 15) for 26 weeks
Summary · context
We compared the effects of weight loss induced with the glucagon-like peptide-1 agonist liraglutide, with that of lifestyle modification, followed by weight maintenance after discontinuing intervention, in obese adults with non-alcoholic fatty liver disease (NAFLD).
Report a problemFND-3072157203
04HumanRandomized controlled trialEfficacy outcome
In obese adults with NAFLD, liraglutide reduced the liver cell death marker cCK-18 at 26 weeks, similar to the reduction with diet and exercise.
In plain wordsIn obese adults with fatty liver, liraglutide lowered a marker of liver cell death about as much as diet and exercise did.
Peptide
Liraglutide
Outcome
DecreaseCaspase-cleaved cytokeratin-18 change at 26 weeks
Study
n = 30
Comparator
Diet and exercise (lifestyle modification)
Outcome group
Liver fat and liver function · Liver
Studied dose
3 mg daily · 26 weeksAs given in this study (human).
Measurements
cCK-18 change
−130 U/L
liraglutide group, 26 weeks
cCK-18 change
−206 U/L
diet and exercise group, 26 weeks
Source sentences
Summary
Diet and exercise and LI groups had significant (P < 0.01) and similar reductions in weight (-3.5 ± 3.3 vs -3.0 ± 2.2 kg), LFF (-8.1 ± 13.2 vs -7.0 ± 7.1%), serum alanine aminotransferase (-39 ± 35 vs -26 ± 33 U/L) and caspase-cleaved cytokeratin-18 (cCK-18) (-206 ± 252 vs -130 ± 158 U/L) at 26 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
or liraglutide 3 mg daily (LI group, n = 15) for 26 weeks
Summary · context
We compared the effects of weight loss induced with the glucagon-like peptide-1 agonist liraglutide, with that of lifestyle modification, followed by weight maintenance after discontinuing intervention, in obese adults with non-alcoholic fatty liver disease (NAFLD).
Report a problemFND-3072157204
05HumanRandomized controlled trialEfficacy outcome
In obese adults with NAFLD, the liraglutide group regained weight at 52 weeks after treatment stopped, whereas weight was unchanged in the diet and exercise group.
In plain wordsIn obese adults with fatty liver, people who stopped liraglutide regained weight by week 52; the diet and exercise group did not.
Peptide
Liraglutide
Outcome
IncreaseWeight regain at 52 weeks after stopping liraglutide
Study
n = 15
Comparator
Diet and exercise (lifestyle modification)
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg daily · 26 weeksAs given in this study (human).
Measurements
Weight regained
1.8 kg
liraglutide group, 52 weeks
Source sentences
Summary
At 52 weeks, the LI group significantly (P < 0.05) regained weight (1.8 ± 2.1 kg), LFF (4.0 ± 5.3%) and cCK-18 (72 ± 126 U/L), whereas these were unchanged in the DE group.
2 context sentences(design, population, supporting numbers)
Summary · context
or liraglutide 3 mg daily (LI group, n = 15) for 26 weeks
Summary · context
We compared the effects of weight loss induced with the glucagon-like peptide-1 agonist liraglutide, with that of lifestyle modification, followed by weight maintenance after discontinuing intervention, in obese adults with non-alcoholic fatty liver disease (NAFLD).
Report a problemFND-3072157205
06HumanRandomized controlled trialEfficacy outcome
In obese adults with NAFLD, liver fat fraction rose again at 52 weeks in the liraglutide group after treatment stopped, but was unchanged in the diet and exercise group.
In plain wordsIn obese adults with fatty liver, liver fat came back after liraglutide stopped; it stayed down with diet and exercise.
Peptide
Liraglutide
Outcome
IncreaseLiver fat fraction regain at 52 weeks after stopping liraglutide
Study
n = 15
Comparator
Diet and exercise (lifestyle modification)
Outcome group
Liver fat and liver function · Liver
Studied dose
3 mg daily · 26 weeksAs given in this study (human).
Measurements
Liver fat fraction regained
4%
liraglutide group, 52 weeks
Source sentences
Summary
At 52 weeks, the LI group significantly (P < 0.05) regained weight (1.8 ± 2.1 kg), LFF (4.0 ± 5.3%) and cCK-18 (72 ± 126 U/L), whereas these were unchanged in the DE group.
2 context sentences(design, population, supporting numbers)
Summary · context
or liraglutide 3 mg daily (LI group, n = 15) for 26 weeks
Summary · context
We compared the effects of weight loss induced with the glucagon-like peptide-1 agonist liraglutide, with that of lifestyle modification, followed by weight maintenance after discontinuing intervention, in obese adults with non-alcoholic fatty liver disease (NAFLD).
Report a problemFND-3072157206
07HumanRandomized controlled trialEfficacy outcome
In obese adults with NAFLD, the liver cell death marker cCK-18 rose again at 52 weeks in the liraglutide group after treatment stopped, but was unchanged in the diet and exercise group.
In plain wordsIn obese adults with fatty liver, a marker of liver cell death rose again after liraglutide stopped; it did not with diet and exercise.
Peptide
Liraglutide
Outcome
IncreasecCK-18 regain at 52 weeks after stopping liraglutide
Study
n = 15
Comparator
Diet and exercise (lifestyle modification)
Outcome group
Liver fat and liver function · Liver
Studied dose
3 mg daily · 26 weeksAs given in this study (human).
Measurements
cCK-18 regained
72 U/L
liraglutide group, 52 weeks
Source sentences
Summary
At 52 weeks, the LI group significantly (P < 0.05) regained weight (1.8 ± 2.1 kg), LFF (4.0 ± 5.3%) and cCK-18 (72 ± 126 U/L), whereas these were unchanged in the DE group.
2 context sentences(design, population, supporting numbers)
Summary · context
or liraglutide 3 mg daily (LI group, n = 15) for 26 weeks
Summary · context
We compared the effects of weight loss induced with the glucagon-like peptide-1 agonist liraglutide, with that of lifestyle modification, followed by weight maintenance after discontinuing intervention, in obese adults with non-alcoholic fatty liver disease (NAFLD).
Report a problemFND-3072157207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 3NCT02654665

Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults

Changi General Hospitaln = 36Mar 2014 to est. Dec 2018

Non-alcoholic Fatty Liver Disease (NAFLD) · Weight Loss · Non-alcoholic Steatohepatitis (NASH)

Trial page ClinicalTrials.govUpdated 30 Jan 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.